

REMARKS

Claims 1-20 are pending. Claims 13 and 14 have been amended to place these claims in better condition for examination. Support for new Claims 15-17 is found in the disclosure on pages 40-42 and 288-289. Support for new composition Claims 18-20 is found on pages 41-42 of the specification. Accordingly, the Applicants do not believe that any new matter has been added. Applicants now respectfully request an early examination on the merits.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

Thomas M. Cunningham
Registration No. 45,394

Tel: 703-413-3000
Fax: 703-413-2220
NFO:TMC:ksh
I:\atty\Tmc\2001-12\217318US-Prel Amend.wpd



Marked-Up Copy

Docket No.: **217318US0 DIV**

Serial No: **New Application**

Amendment Filed: **Herewith**

IN THE CLAIMS

Please amend Claims 13 and 14 as follows:

--13. (Amended) A method for treating a disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity or antiallergic activity, comprising:

administering an effective amount [by the use] of the sulfonamide compound of claim 1 or a pharmaceutically acceptable salt thereof to a subject in need thereof.

14. (Amended) A method for producing a therapeutic agent comprising admixing the sulfonamide compound of claim 1 with a pharmaceutically acceptable excipient or carrier [use of the sulfonamide compound of claim 1 or a pharmaceutically acceptable salt thereof for the production of a therapeutic agent or a disease treatable based on a blood sugar level-depressing activity, or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity or antiallergic activity].--

--Claims 15-20 (New).--

